Zacks Investment Research upgraded shares of Abcam PLC (NASDAQ:ABCZY) from a sell rating to a buy rating in a research report sent to investors on Tuesday morning. They currently have $16.00 price objective on the stock.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Shares of Abcam PLC (ABCZY) opened at 14.035 on Tuesday. The stock has a 50 day moving average of $13.96 and a 200-day moving average of $12.41. Abcam PLC has a 52 week low of $9.13 and a 52 week high of $14.68. The company has a market capitalization of $2.84 billion and a price-to-earnings ratio of 54.824.
Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with MarketBeat.com's FREE daily email newsletter.